AHL
CMPX icon

Abel Hall LLC’s Compass Therapeutics CMPX Stock Holding History

Abel Hall LLC’s Portfolio CMPX Stock Details CMPX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$55.7K Sell
10,524
-12,358
-54% -$71.3K 0.01% 736
2025
Q4 		$123K Buy
+22,882
New +$106K 0.03% 596

Other funds holding CMPX

TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $352M AUM 220.14% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Abel Hall LLC's CMPX Position: Q1 2026 in Review

Abel Hall LLC reduced its Compass Therapeutics (CMPX) stake by 54% in Q1 2026, selling an estimated $71.3K and leaving 10,524 shares worth $55.7K. The position accounts for 0.01% of the portfolio, ranked #736.

Abel Hall LLC first reported a position in CMPX in Q4 2025 and has held it in 2 quarters since. The position peaked at $123K in Q4 2025. 201 funds tracked by Wall St. Rank hold CMPX as of Q1 2026.

  • Abel Hall LLC held 10,524 shares of Compass Therapeutics worth $55.7K as of Q1 2026.
  • Abel Hall LLC sold 12,358 Compass Therapeutics shares in Q1 2026, an estimated $71.3K.
  • Compass Therapeutics made up 0.01% of Abel Hall LLC's portfolio in Q1 2026, its #736 holding.
  • Abel Hall LLC first reported a position in Compass Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • Abel Hall LLC's Compass Therapeutics position peaked at $123K in Q4 2025.
  • 201 funds tracked by Wall St. Rank held Compass Therapeutics as of Q1 2026.

Based on Abel Hall LLC's 13F filing for Q1 2026, filed 28 Apr 2026.